

Rohit Loomba

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4715673/publications.pdf>

Version: 2024-02-01

61
papers

3,383
citations

201674

27
h-index

182427

51
g-index

61
all docs

61
docs citations

61
times ranked

2986
citing authors

#	ARTICLE	IF	CITATIONS
1	Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 223-238.	17.8	867
2	Advancing the global public health agenda for NAFLD: a consensus statement. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 60-78.	17.8	330
3	Advances in non-invasive assessment of hepatic fibrosis. <i>Gut</i> , 2020, 69, 1343-1352.	12.1	179
4	Collagen biology and non-invasive biomarkers of liver fibrosis. <i>Liver International</i> , 2020, 40, 736-750.	3.9	107
5	Review article: the emerging role of genetics in precision medicine for patients with non-alcoholic steatohepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1305-1320.	3.7	103
6	Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1149-1159.	3.7	101
7	Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial. <i>Nature Medicine</i> , 2021, 27, 1825-1835.	30.7	98
8	Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator-activated receptor β modulator (SPPARM β), versus placebo in patients with non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 1263-1277.	3.7	90
9	NAFLD: Reporting Histologic Findings in Clinical Practice. <i>Hepatology</i> , 2021, 73, 2028-2038.	7.3	86
10	Serum bile acid patterns are associated with the presence of NAFLD in twins, and dose-dependent changes with increase in fibrosis stage in patients with biopsy-proven NAFLD. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 183-193.	3.7	80
11	Multicenter Validation of Association Between Decline in MRI-PDFF and Histologic Response in NASH. <i>Hepatology</i> , 2020, 72, 1219-1229.	7.3	79
12	Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 1150-1161.	3.7	79
13	MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis. <i>Gut</i> , 2021, 70, 1946-1953.	12.1	78
14	rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis. <i>Journal of Hepatology</i> , 2021, 74, 20-30.	3.7	77
15	Differential Activation of Hepatic Invariant NKT Cell Subsets Plays a Key Role in Progression of Nonalcoholic Steatohepatitis. <i>Journal of Immunology</i> , 2018, 201, 3017-3035.	0.8	69
16	The Commensal Microbe <i>Veillonella</i> as a Marker for Response to an FGF19 Analog in NASH. <i>Hepatology</i> , 2021, 73, 126-143.	7.3	58
17	Clinical and metabolic effects associated with weight changes and obeticholic acid in non-alcoholic steatohepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 645-656.	3.7	54
18	Systematic review with network meta-analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 880-889.	3.7	51

#	ARTICLE	IF	CITATIONS
19	Review article: emerging role of the gut microbiome in the progression of nonalcoholic fatty liver disease and potential therapeutic implications. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 144-158.	3.7	50
20	Hepatic Fibrosis Associates With Multiple Cardiometabolic Disease Risk Factors: The Framingham Heart Study. <i>Hepatology</i> , 2021, 73, 548-559.	7.3	49
21	Clinical utility of 30% relative decline in MRI-PDFF in predicting fibrosis regression in non-alcoholic fatty liver disease. <i>Gut</i> , 2022, 71, 983-990.	12.1	45
22	Emerging Role of Genomic Analysis in Clinical Evaluation of Lean Individuals With NAFLD. <i>Hepatology</i> , 2021, 74, 2241-2250.	7.3	41
23	Links between gut microbiome composition and fatty liver disease in a large population sample. <i>Gut Microbes</i> , 2021, 13, 1-22.	9.8	41
24	Liver stiffness by magnetic resonance elastography is associated with increased risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 1030-1037.	3.7	40
25	Longitudinal association of magnetic resonance elastography-associated liver stiffness with complications and mortality. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 292-301.	3.7	38
26	Non-Invasive Biomarkers of Nonalcoholic Steatohepatitis: the FNIH NIMBLE project. <i>Nature Medicine</i> , 2022, 28, 430-432.	30.7	33
27	Meta-analysis: prevalence of, and risk factors for, nonalcoholic fatty liver disease in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 894-907.	3.7	32
28	A small molecule targeting ALOX12-ACC1 ameliorates nonalcoholic steatohepatitis in mice and macaques. <i>Science Translational Medicine</i> , 2021, 13, eabg8116.	12.4	30
29	Comparative efficacy of an optimal exam between ultrasound versus abbreviated MRI for HCC screening in NAFLD cirrhosis: A prospective study. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 820-827.	3.7	30
30	Magnetic resonance elastography plus Fibrosis-4 versus FibroScan-aspartate aminotransferase in detection of candidates for pharmacological treatment of NASH-related fibrosis. <i>Hepatology</i> , 2022, 75, 661-672.	7.3	29
31	Standardising the interpretation of liver biopsies in nonalcoholic fatty liver disease clinical trials. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 1100-1111.	3.7	27
32	Clinical Utility of Mac-2 Binding Protein Glycosylation Isomer in Chronic Liver Diseases. <i>Annals of Laboratory Medicine</i> , 2021, 41, 16-24.	2.5	27
33	Have incidence rates of liver cancer peaked in the United States?. <i>Cancer</i> , 2020, 126, 3151-3155.	4.1	26
34	Plasma eicosanoids as noninvasive biomarkers of liver fibrosis in patients with nonalcoholic steatohepatitis. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482092390.	3.2	24
35	NASHFit: A randomized controlled trial of an exercise training program to reduce clotting risk in patients with NASH. <i>Hepatology</i> , 2022, 76, 172-185.	7.3	24
36	Multiple omics study identifies an interspecies conserved driver for nonalcoholic steatohepatitis. <i>Science Translational Medicine</i> , 2021, 13, eabg8117.	12.4	23

#	ARTICLE	IF	CITATIONS
37	Assessment of treatment response in nonalcoholic steatohepatitis using advanced magnetic resonance imaging. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 844-854.	3.7	21
38	Review article: current and emerging therapies for the management of cirrhosis and its complications. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1099-1115.	3.7	20
39	The impact of genetic risk on liver fibrosis in nonalcoholic fatty liver disease as assessed by magnetic resonance elastography. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 68-77.	3.7	18
40	Prognostic utility of magnetic resonance elastography and MEFIB index in predicting liver-related outcomes and mortality in individuals at risk of and with nonalcoholic fatty liver disease. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482210938.	3.2	18
41	Clinical Research in Hepatology in the COVID-19 Pandemic and Post-Pandemic Era: Challenges and the Need for Innovation. <i>Hepatology</i> , 2020, 72, 1819-1837.	7.3	17
42	Elevated Glycated Hemoglobin Is Associated With Liver Fibrosis, as Assessed by Elastography, in a Population-Based Study of Mexican Americans. <i>Hepatology Communications</i> , 2020, 4, 1793-1801.	4.3	17
43	Meta-analysis: analysis of mechanistic pathways in the treatment of nonalcoholic steatohepatitis. Evidence from a Bayesian network meta-analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1076-1087.	3.7	15
44	Reliability of histologic assessment for NAFLD and development of an expanded NAFLD activity score. <i>Hepatology</i> , 2022, 76, 1150-1163.	7.3	15
45	Direct Comparison of Quantitative US versus Controlled Attenuation Parameter for Liver Fat Assessment Using MRI Proton Density Fat Fraction as the Reference Standard in Patients Suspected of Having NAFLD. <i>Radiology</i> , 2022, , 211131.	7.3	12
46	Hepatocellular Carcinoma Risk Assessment for Patients With Advanced Fibrosis After Eradication of Hepatitis C Virus. <i>Hepatology Communications</i> , 2022, 6, 461-472.	4.3	10
47	Financial Hardship From Medical Bills Among Adults With Chronic Liver Diseases: National Estimates From the United States. <i>Hepatology</i> , 2021, 74, 1509-1522.	7.3	9
48	Comparison of clinical prediction rules for ruling out cirrhosis in nonalcoholic fatty liver disease (NAFLD). <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1441-1451.	3.7	9
49	Emerging Metabolic and Transcriptomic Signature of PNPLA3-Associated NASH. <i>Hepatology</i> , 2021, 73, 1248-1250.	7.3	3
50	Noninvasive Risk Stratification for Nonalcoholic Fatty Liver Disease Among Living Liver Donor Candidates: A Proposed Algorithm. <i>Liver Transplantation</i> , 2022, 28, 670-677.	2.4	3
51	Editorial: role of leucine-metformin-sildenafil combination in the treatment of nonalcoholic fatty liver disease (NAFLD). <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 378-379.	3.7	1
52	Editorial: further evidence for the use of advanced magnetic resonance imaging techniques to monitor NAFLD – authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1271-1272.	3.7	0
53	Editorial: nonalcoholic fatty liver disease – a pandemic in need of novel treatments and endpoints. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 65-66.	3.7	0
54	Editorial: evolving histological assessment of NASH. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 1245-1246.	3.7	0

#	ARTICLE	IF	CITATIONS
55	Letter: probiotics? Yes, but which ones? Authors'™ reply. Alimentary Pharmacology and Therapeutics, 2019, 50, 968-968.	3.7	0
56	Editorial: how widespread and serious is non-€alcoholic fatty liver disease in the real world? Authors' reply. Alimentary Pharmacology and Therapeutics, 2020, 51, 1200-1201.	3.7	0
57	Editorial: evolution of GLP-1 receptor agonists as pharmacotherapy for NASH beyond diabetes mellitus and obesity - authors'™ reply. Alimentary Pharmacology and Therapeutics, 2021, 54, 1498-1498.	3.7	0
58	Utilizing Macrosteatotic Allografts for Nonalcoholic Steatohepatitis Recipients. Liver Transplantation, 2022, 28, 552-553.	2.4	0
59	Editorial: screening for hepatocellular carcinoma in <scp>NAFLD</scp> cirrhosis-™ towards abbreviated <scp>MRI</scp> alternative in patients with obesity? Authors' reply. Alimentary Pharmacology and Therapeutics, 2022, 55, 1212-1213.	3.7	0
60	Editorial: liver stiffness by magnetic resonance elastography and cardiovascular risk in non-€alcoholic fatty liver disease-™ simply associated or more complicated? Authors' reply. Alimentary Pharmacology and Therapeutics, 2021, 53, 1230-1231.	3.7	0
61	Letter: non-€invasive prediction models to exclude cirrhosis in <scp>NAFLD</scp> -™ not everyone fits the mould. Authors' reply. Alimentary Pharmacology and Therapeutics, 2022, 56, 182-183.	3.7	0